Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.44 USD
−62.26 M USD
163.91 M USD
141.35 M
About Xeris Biopharma Holdings, Inc.
Sector
Industry
CEO
John Patrick Shannon
Website
Headquarters
Chicago
Founded
2005
FIGI
BBG012V1MG52
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
X
XERS5008737
Xeris Pharmaceuticals, Inc. 5.0% 15-JUL-2025Yield to maturity
0.93%
Maturity date
Jul 15, 2025
XERS5927663
Xeris Biopharma Holdings, Inc. 8.0% 15-JUL-2028Yield to maturity
−0.49%
Maturity date
Jul 15, 2028
Explore more bonds
Frequently Asked Questions
The current price of XERS is 3.43 USD — it has decreased by −2.00% in the past 24 hours. Watch Xeris Biopharma Holdings, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Xeris Biopharma Holdings, Inc. stocks are traded under the ticker XERS.
XERS stock has risen by 2.39% compared to the previous week, the month change is a 6.19% rise, over the last year Xeris Biopharma Holdings, Inc. has showed a 49.78% increase.
We've gathered analysts' opinions on Xeris Biopharma Holdings, Inc. future price: according to them, XERS price has a max estimate of 6.60 USD and a min estimate of 3.00 USD. Watch XERS chart and read a more detailed Xeris Biopharma Holdings, Inc. stock forecast: see what analysts think of Xeris Biopharma Holdings, Inc. and suggest that you do with its stocks.
XERS reached its all-time high on Sep 12, 2018 with the price of 27.98 USD, and its all-time low was 0.97 USD and was reached on Jan 5, 2023. View more price dynamics on XERS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
XERS stock is 3.70% volatile and has beta coefficient of 1.98. Track Xeris Biopharma Holdings, Inc. stock price on the chart and check out the list of the most volatile stocks — is Xeris Biopharma Holdings, Inc. there?
Today Xeris Biopharma Holdings, Inc. has the market capitalization of 521.78 M, it has increased by 6.77% over the last week.
Yes, you can track Xeris Biopharma Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
Xeris Biopharma Holdings, Inc. is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
XERS earnings for the last quarter are −0.11 USD per share, whereas the estimation was −0.09 USD resulting in a −26.92% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about Xeris Biopharma Holdings, Inc. earnings.
Xeris Biopharma Holdings, Inc. revenue for the last quarter amounts to 52.86 M USD, despite the estimated figure of 51.45 M USD. In the next quarter, revenue is expected to reach 56.74 M USD.
XERS net income for the last quarter is −15.74 M USD, while the quarter before that showed −15.01 M USD of net income which accounts for −4.89% change. Track more Xeris Biopharma Holdings, Inc. financial stats to get the full picture.
No, XERS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 28, 2024, the company has 377.00 employees. See our rating of the largest employees — is Xeris Biopharma Holdings, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Xeris Biopharma Holdings, Inc. EBITDA is −32.41 M USD, and current EBITDA margin is −18.82%. See more stats in Xeris Biopharma Holdings, Inc. financial statements.
Like other stocks, XERS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Xeris Biopharma Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Xeris Biopharma Holdings, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Xeris Biopharma Holdings, Inc. stock shows the buy signal. See more of Xeris Biopharma Holdings, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.